Literature DB >> 18641820

Peribulbar versus general anesthesia for horizontal strabismus surgery.

Keila Monteiro de Carvalho1, Tatiana Millán, Nilza Minguini, Tais Hitomi Wakamatsu.   

Abstract

PURPOSE: To compare the results of strabismus surgery under peribulbar and general anesthesia in cases of small and moderate angle of horizontal strabismus.
METHODS: Medical records of eighty-four patients with small and moderate angle horizontal strabismus who underwent strabismus surgery were reviewed. Forty-two patients were submitted to the surgery under peribulbar anesthesia and forty-two under general anesthesia. The surgery was considered satisfactory when postoperative angle was 10 prism diopters or less.
RESULTS: Surgery was satisfactory in all patients. Mann-Whitney test showed no difference in the preoperative angle of deviation (p=0.366) and in the postoperative results (p=0.800) between the two groups. Adjusting for the variables age and type of strabismus (esotropia and exotropia), ANCOVA (analysis of covariance) results showed no statistical difference (p=0.368). There were no complications due to surgery or anesthesia in either group.
CONCLUSIONS: This study suggested that there was no difference between the postoperative results of strabismus surgery under peribulbar and general anesthesia in small and moderate angle of horizontal strabismus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18641820     DOI: 10.1590/s0004-27492008000300009

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  2 in total

1.  Anesthetic Approach in Ambulatory Vitrectomy: Peribulbar Block vs. Balanced General Anesthesia.

Authors:  Bárbara Gouveia; Leonardo Ferreira; Paula Maia
Journal:  Anesthesiol Res Pract       Date:  2022-03-28

2.  Results of monocular surgery under peribulbar anesthesia for large-angle horizontal strabismus.

Authors:  Tatiana Millán; Keila Monteiro de Carvalho; Nilza Minguini
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.